For ARDSNet Members

Enteral Omega-3 Fatty Acid, γ-Linolenic Acid, and Antioxidant Supplementation in Acute Lung Injury. Todd W. Rice, MD, MSc; Arthur P. Wheeler, MD; B. Taylor Thompson, MD; Bennett P. deBoisblanc, MD; Jay Steingrub, MD; Peter Rock, MD, MBA, for the NHLBI ARDS Clinical Trials Network. AMA. 2011;306(14):1574-1581. Published online October 5, 2011.

The ARDSNet Omega-3 trial noted above was presented at the European Congress of Intensive Care Medicine in Berlin last week by Dr. Todd Rice. The manuscript has been accepted by JAMA and is available online on their website: http://jama.ama-assn.org/

The ARDS Network website has a new look! Content has been reorganized to make it easier to navigate and it has received a new design. A few new things:
* The public view now has a "Clinicians and Researchers" section that contains more technical information and tools.
* All the information for requesting data and samples has been relocated onto the new "Data and Sample Requests" page (also under the clinicians and researchers section).
* Relevant news for the public is located on the public home page (click on the word Home in the upper left hand corner just under the logo).

We hope this change will facilitate more ease and efficiency when using our website.

Some recent happenings in the ARDS Network:

• ATS 2011: The ARDS Network's noon session at the ATS International meeting in Denver was very well attended. David Schoenfeld discussed early stopping and interim analysis considerations for ARDSNet trials and Todd Rice and Adrienne Randolph presented the findings from the H1N1 registries. Numerous questions followed presentations.

• EDEN early vs. later feeding study completed: The EDEN database was locked on may 18th and released to the PIs (Art Wheeler and Todd Rice) on May 26th. Todd and Art will work with the EDEN writing committee to interpret the results in advance of a presentation to the Steering Committee soon. The DSMB will conduct a courtesy review of the data in late June.

The ARDSNet trial used an omega 3 and antioxidant supplement added to "usual" feeding (not any commercially available product). The study stopped for futility. "Futility" means there was no realistic chance that the intervention could be proven to be beneficial with the size trial we had planned. It would not be appropriate to make any conclusions about any other feeding product based upon our study, as it would also be inappropriate to conclude that our treatment was "harmful". The database for our study is not yet locked but once that is done we will be publishing our results which when viewed in their entirety may or may not influence your thinking about this topic.

Data from these two ARDSNet studies have been made available to the public. Go to the NHLBI web site (http://www.nhlbi.nih.gov/resources/deca/default.htm) for instructions on accessing these datasets.

Please see the attached listing of presentations/posters.

Hi! The website is back up. We've upgraded to Drupal 5.1. If you run into any problems, please let me know.

Ricky

Hi! The ARDSNet website will be down for a few hours tomorrow, Wed 2 May 2007, for an upgrade.

Hi! We've removed the ability for users to request new accounts through the website. If you want an account and are a member of the NHLBI ARDSNet, please contact the webmaster at ards-webmaster@hedwig.mgh.harvard.edu. Please make the subject be "ardsnet website account request". The NHLBI ARDSNet is a research network, and you must be a member of the network to receive an account.

Hi! As a part of the website upgrade, we decided to change how we were dealing with the publications to take advantage of some new capabilities of Drupal. This took a while to get in place, but the publications are now available! The new publications system has all kinds of cool abilities — click on "read more" to see a short list.